Cantargia is a clinical-stage biotechnology company listed on the Nasdaq Stockholm main market. It is developing CAN04 and CAN10 against IL1RAP. CAN04 is in a Phase IIa clinical trial, CANFOUR, in solid tumours focused on NSCLC and PDAC. It is preparing to file an IND and initiate a trial in the US next year.
Cantargia is developing antibodies against IL1RAP. Cantargia has provided updated interim data from its Phase IIa CANFOUR trial, reporting new efficacy data from the combination arms of the study investigating CAN04 (anti-IL1RAP) in first-line NSCLC and PDAC. These new Phase IIa data, combined with initial data reported in December 2019, continue to support the hypothesis that CAN04 has a synergistic benefit with chemotherapy, in our view. Final analysis and key efficacy data are expected in 2021. Cantargia is preparing to engage with regulators to discuss Phase III development plans. Another tailwind is increasing positive sentiment on Novartis’s canakinumab (anti-IL1beta) progressing in its Phase III trials for NSCLC, expected to readout data in 2021. Cantargia completed a directed share issue in December 2020, raising SEK564m gross proceeds to start a broader trial programme in new cancer indications, including TNBC.
Increasing the understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.